Greenwood Village, Co., USA – Ampio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced the appointment of Gregory A. Gould as CFO, treasurer, and corporate secretary, effective June 10, 2014. [break]
Mr. Gould has more than eighteen years of senior management experience at public pharmaceutical and life sciences companies, where he has demonstrated success leading accounting and finance organizations, inclusive of fundraising, licensing transactions, and acquisitions. Most recently Mr. Gould served as the Interim President and Chief Executive Officer and Chief Financial Officer of SeraCare Life Sciences, Inc. in Milford, Massachusetts.
Prior to his time at SeraCare, Mr. Gould was the Chief Financial Officer of Atrix Laboratories, Inc. in Fort Collins, Colorado. During Mr. Gould’s tenure at Atrix he was instrumental in the negotiation and sale of the company to QLT, Inc. He also played a critical role in the management of several licensing agreements including the global licensing agreement with Sanofi - June 6, 2014, Greenwood Village, Co., USA – Ampio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced the appointment of Gregory A. Gould as CFO, treasurer, and corporate secretary, effective June 10, 2014.
Article continues below
]
Mr. Gould has more than eighteen years of senior management experience at public pharmaceutical and life sciences companies, where he has demonstrated success leading accounting and finance organizations, inclusive of fundraising, licensing transactions, and acquisitions. Most recently Mr. Gould served as the Interim President and Chief Executive Officer and Chief Financial Officer of SeraCare Life Sciences, Inc. in Milford, Massachusetts.
Prior to his time at SeraCare, Mr. Gould was the Chief Financial Officer of Atrix Laboratories, Inc. in Fort Collins, Colorado. During Mr. Gould’s tenure at Atrix he was instrumental in the negotiation and sale of the company to QLT, Inc. He also played a critical role in the management of several licensing agreements including the global licensing agreement with Sanofi-Synthelabo of the Eligard products.
Prior to joining Atrix he held positions of increasing responsibility in finance and accounting at Colorado MedTech in Boulder, Colorado, a publicly traded medical device design and manufacturing company. Mr. Gould began his career as an auditor with Arthur Andersen, LLP. He currently serves on the board of directors of CytoDyn, Inc., a publicly traded drug development company pursuing ant-viral agents for the treatment of HIV.
Mr. Gould graduated from the University of Colorado with a BS in Business Administration and is a Certified Public Accountant. ■